THE NATIONAL FOUNDATION FOR CANCER RESEARCH


Associated tags: Oncology, Research, Health, Science, Biotechnology, NFCR, Thought, Diagnosis, NIH, National Press Club (United States), Marie Cassidy, Women Leaders in Global Health Conference, Arizona State University, NCI, University of California, San Diego, Adaptation, Distinguishing, Pharmaceutical, Patient, Principal

AIM-HI Accelerator Fund Honors Anna D. Barker, Ph.D., with Inaugural Beacon Award for Women Leaders in Oncology

Retrieved on: 
Wednesday, October 12, 2022
Oncology, Health, Consumer, Women, Research, Science, National Foundation for Cancer Research, Complex adaptive system, National, Program, Mortality, AoC Beacon Awards, Woman, Translation, University, The Cancer Genome Atlas, CEO, Nanotechnology, National Human Genome Research Institute, Press club, Solution, Cancer, Proteomics, GBM, Drug development, Oncology, Brain, Food and Drug Administration, Learning, NHGRI, National Cancer Institute, Industry, Nature, TCGA, FDA, Â, Principal, Thought, Diagnosis, Organization, Research, NIH, Goal, National Press Club (United States), Marie Cassidy, Women Leaders in Global Health Conference, Arizona State University, NCI, University of California, San Diego, Adaptation, NFCR, Distinguishing, Patient, Food, Health, Tomorrow's India Global Summit, Adult, Gold, Glioblastoma, Neurosurgery, Lawrence, Pharmaceutical industry

The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of its inaugural Beacon Award for Women Leaders in Oncology as Anna D. Barker, Ph.D., Chief Strategy Officer at the Lawrence J. Ellison Institute for Transformative Medicine .

Key Points: 
  • The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of its inaugural Beacon Award for Women Leaders in Oncology as Anna D. Barker, Ph.D., Chief Strategy Officer at the Lawrence J. Ellison Institute for Transformative Medicine .
  • The Beacon Award for Women Leaders in Oncology was established in 2022 by the AIM-HI Accelerator Fund , a translational research affiliate of the National Foundation for Cancer Research , to bridge the funding gap in translating innovations from the lab to the clinic and amplify women leaders and entrepreneurs.
  • It is my honor to accept this inaugural award on behalf of the patients I serve in all my efforts.
  • AIM-HI Accelerator Fund is bridging the gap between innovative cancer discoveries and high-impact cancer treatments and technologies.

Pioneering Engineer-Researcher to Receive 2022 Szent-Györgyi Prize for Progress in Cancer Research

Retrieved on: 
Monday, August 15, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health

The National Foundation for Cancer Research (NFCR) announced today that Rakesh K. Jain, Ph.D., has been selected to receive the 2022 Szent-Gyrgyi Prize for Progress in Cancer Research.

Key Points: 
  • The National Foundation for Cancer Research (NFCR) announced today that Rakesh K. Jain, Ph.D., has been selected to receive the 2022 Szent-Gyrgyi Prize for Progress in Cancer Research.
  • Dr. Rakesh Jains seminal discoveries in basic and translational research have guided numerous fields in cancer research with the promise of saving lives.
  • These are the pillars of the Szent-Gyrgyi Prize, said Sujuan Ba, Ph.D., co-chair of the 2022 Prize selection committee and President and CEO of NFCR.
  • The Szent-Gyrgyi Prize for Progress in Cancer Research was established by the National Foundation for Cancer Research in honor of its co-founder, Albert Szent-Gyrgyi, M.D., Ph.D., recipient of the 1937 Nobel Prize for Physiology and Medicine.